# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Madam C. J. Walker (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET019-SYN
- Date: 2026-02-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harriet Okonjo-Bell, MD
- Calendar frame: modern shifted

## Reason for visit

Establishing care for high blood pressure found at a workplace screening, morning headaches and protein in the urine at last year's executive physical, in a company founder who travels most weeks. **S**

## Historical basis

- Madam C. J. Walker was born Sarah Breedlove on December 23, 1867, in Delta, Louisiana, the daughter of Owen and Minerva Anderson Breedlove. Both parents had been enslaved on a Madison Parish plantation, and she was their first child born into freedom. **D**
- Both her parents had died by the time she was seven, and she went to live with an older sister and moved across the river to Vicksburg, Mississippi. She married Moses McWilliams at fourteen, had her only child, Lelia (later A'Lelia), and was widowed at twenty. She then moved to St. Louis, where she worked as a laundress and cook, sometimes for as little as a dollar a day. **D**
- While working as a laundress she began to lose her hair, a problem many Black women of her time shared. Her biographers attribute it to scalp disease such as dandruff, poor diet, a hard life and harsh washing products, in an era when most homes lacked indoor plumbing. In 1904 she began using and selling another Black woman's hair grower as a sales agent, then developed her own sulfur-containing ointments and shampoos to treat scalp disease. **D**
- In Denver she married Charles Joseph Walker, a newspaper advertising salesman (in January 1906, or 1905 in one account), and began calling herself Madam Walker, in part to avoid the familiar forms of address then used for Black women. She launched her own hair-care line there, set up headquarters and a training school for her agents in Pittsburgh in 1908, and moved the company to Indianapolis in 1910. She trained thousands of sales agents, "hair culturists," who earned a share of the profits. She kept the name after the marriage ended. **D**
- As her wealth grew she became a philanthropist and activist: she gave to the YWCA and paid tuition for students at Tuskegee Institute, and in 1915 she sued over discrimination at an Indianapolis theater. **D**
- The physical demands she placed on herself undermined her health, and she suffered from high blood pressure. She went for a rest cure at Hot Springs, Arkansas, in 1916, but otherwise did not slow her pace. **D**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- She wants to keep building her company and keep traveling to her agents, and does not want to be told to slow down. **S**
- She is worried that her kidneys could fail and wants to know plainly what the numbers mean. **S**
- She wants a plan that works on the road: medicines, readings, food and tests. **S**

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Medications and allergies

- No medications before this visit. **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1904: Hair loss and scalp disease in her thirties, while working as a laundress; resolved **D** (CLM-0003)
- 1916: High blood pressure, for which she took a rest cure at Hot Springs, Arkansas, the year before this visit; no treatment recorded **D** (CLM-0006)

## Procedures and immunizations

- 2026-02-09 to 2026-02-09: Twelve-lead electrocardiogram **S**
- 2026-02-09: Influenza vaccine, inactivated, this season **S**

## Family history

- mother: Died when she was a young child; cause not recorded in the cited source **D** (CLM-0002)
- father: Died when she was a young child; cause not recorded in the cited source **D** (CLM-0002)

## Measurements

Sodium: 140 mmol/L; Potassium: 4.4 mmol/L; Bicarbonate (total CO2): 25 mmol/L; Creatinine: 1.22 mg/dL (high); Glucose: 94 mg/dL; eGFR (CKD-EPI 2021, race-free): 54 mL/min/1.73 m² (low); Urine albumin-to-creatinine ratio: 286 mg/g (high); Hemoglobin A1c: 5.4%; Total cholesterol: 250 mg/dL (high); LDL cholesterol: 174 mg/dL (high); HDL cholesterol: 46 mg/dL (low); Triglycerides: 150 mg/dL (high); Hemoglobin: 12.4 g/dL; TSH: 1.9 mIU/L; PHQ-9: 4. All results are synthetic.

BP 166/102 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 79 kg; BMI 29.7 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, direct, organized and quick; asks for the numbers and the reasons; mood steady; PHQ-9 score 4. Functional status: Independent in all daily activities; works long days and travels most weeks; no limitation in walking or climbing stairs. Physical examination is intentionally limited. **S**

## Assessment

1. Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirm; status draft. **S**
2. Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 2021 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigated; status draft. **S**
3. Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate); status draft. **S**

## Plan

- Nephrology consultation at the two-week visit for albuminuria and a reduced eGFR found at 49: the likely cause, whether more tests or a biopsy are needed, kidney-protective treatment, APOL1 testing, and monitoring that fits her travel. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Confirm the diagnosis outside the office: 24-hour ambulatory monitoring on a day at home, and a validated upper-arm home monitor with a correctly sized cuff that travels with her, two readings morning and evening for seven days, travel days included; recheck in two weeks. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Kidney evaluation: repeat urine albumin and creatinine at two weeks, compared with last year's results to establish chronicity; urinalysis; kidney ultrasound; calcium, phosphate, parathyroid hormone and 25-hydroxyvitamin D at baseline; every eGFR reported by the race-free CKD-EPI 2021 equation; no ibuprofen or naproxen. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021); A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Heart and vascular risk: ECG at intake and an echocardiogram for the left ventricular hypertrophy it shows; a fundus examination; TSH and A1c at diagnosis; lipid panel and 10-year ASCVD risk by the Pooled Cohort Equations. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Food: sodium under 2 g a day built on what she eats, not a new diet: a salt-free seasoning blend for the dishes she cooks on Sundays, smoked turkey in small amounts in place of salt pork, ordering strategies for banquets and restaurants, water instead of a third coffee on travel days; video sessions with a registered dietitian between trips; no potassium-based salt substitutes until her kidney tests and any new medicines are settled. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024) **S**
- Work and rest on her terms: she sets her schedule; the risks of uncontrolled blood pressure and kidney disease are stated plainly and any medicines are chosen to do the work, timed to her home clock across time zones, with a written sick-day card for her bag; a protected sleep window on travel nights and walking during layovers; video visits between trips and laboratory checks on her days at home. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024) **S**
- Mood and stress: PHQ-9 at intake and yearly. Guideline: CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Vaccines: influenza today; pneumococcal, hepatitis B and Tdap needs reviewed at the preventive visit; influenza and COVID-19 each autumn. Guideline: Adult Immunization Schedule by Age (2026) **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021), Inker LA et al., N Engl J Med 2021
- A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021), National Kidney Foundation and American Society of Nephrology (Am J Kidney Dis 2022)
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018), American College of Cardiology and American Heart Association (Circulation 2019)
- CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention
